LYCOS RETRIEVER 
Zyprexa: British Fda
built 668 days ago
As early as 2002, two international bodies issued warnings about Zyprexa and diabetes-related complications. Those international bodies were the Japanese Health and Welfare Ministry and the Great Britain Medicines Control Agency. Because of these warnings, Eli Lilly changed Zyprexa's labels in the United Kingdom and Japan to include the risk of diabetes-related complications. However, the company did not notify the United States FDA about the matter.
Source:
The Complaint alleges that for over a decade, Eli Lilly knew of links between Zyprexa and extreme weight gain and diabetes. In addition, during the Class Period, the Company engaged in a scheme to market Zyprexa for uses that were not approved by the FDA, in violation of FDA regulations that proscribed such marketing. Federal and state regulators have commenced law suits against Lilly based on these marketing schemes and the Company has denied any wrongdoing....
Source:
[O]f the 2001 Duke report, the FDA continued to monitor Zyprexa users to determine the risk factor in terms of developing diabetes. In September of 2003, the FDA felt compelled to advise Eli Lilly and Co to amend their Zyprexa warning so as to include information about the increased risk of developing diabetes and insulin resistance. It wasn't until March of 2004 that Eli Lilly and Co finally decided to heed the FDA's advice by issuing a "Dear Doctor" letter that warned of the relationship between Zyprexa and diabetes.
Source:
Studies ... linked Zyprexa to pancreatic and other severe complications, according to lawsuits. Eli Lilly was not only under attack for the serious side effects while taking Zyprexa for FDA intended uses, but also for its "off-label" complications. Prescribing drugs off-label is a common practice, but companies are not allowed to promote its drugs for conditions it was not approved for.
Source:
The FDA originally approved Zyprexa® for two conditions only: schizophrenia and bipolar disorder. Lilly later obtained approval to market Zyprexa® as a "mood stabilizer," meaning that even those without a "psychosis" can legitimately take an "anti-psychotic" drug.
Source:
As the company sought to turn Zyprexa into the "number one neuroscience drug in history," its strategy rested squarely in how much of the market for treating bipolar disorder it could carve off for Zyprexa. To do that, they cast Zyprexa as a long-term "mood stabilzer" far in advance of an FDA approval that would permit such language. Along the way, the company downplayed known risks associated with the drug.
Source:
MORE ABOUT
British Fda